TECVAYLI – Talk Bio

J&J Reports Positive Phase 3 MajesTEC-9 Results for Tecvayli in Earlier Multiple Myeloma

1 week ago talkbio0Tagged J&J, Multiple Myeloma, Oral region, PFS, Phase 3, TECVAYLI

Tecvayli; J&J; Phase 3; MajesTEC-9; multiple myeloma; PFS; OS

J&J’s Tecvayli and Darzalex Combo Wins FDA’s Proactive National Priority Voucher for Relapsed/Refractory Multiple Myeloma

1 month ago talkbio0Tagged Asymmetric Septal Hypertrophy, CNPV, Darzalex, J&J, Multiple Myeloma, National Priority Voucher, TECVAYLI, United States Food and Drug Administration

J&J; FDA; National Priority Voucher; Tecvayli; Darzalex; Multiple Myeloma; CNPV; ASH 2025

Johnson & Johnson Highlights Promising Combination of TALVEY and TECVAYLI for Relapsed or Refractory Multiple Myeloma

1 year ago talkbio0Tagged Antibodies, Bispecific, Combined, EMD, Extramedullary Disease in Plasma Cell Myeloma, Frequency of Responses, Refractory Plasma Cell Myeloma, Relapsing course, Response process, Talquetamab, TALVEY, Teclistamab, TECVAYLI

TALVEY (talquetamab), TECVAYLI (teclistamab), Relapsed or Refractory Multiple Myeloma (RRMM), Bispecific Antibody Combination, Extramedullary Disease (EMD), High Response Rates, Durable Responses